Loading…
KPRX
Kiora Pharmaceuticals Inc
NASDAQ· Healthcare· Biotechnology· CUSIP 49721T507
$2.62-1.50%Price as of Aug 29, 18:43 UTC · updated once a day, after the close
Key metrics
- Market cap
- $11.59M
- P/E
- —
- Forward P/E
- —
- P/B
- 0.8x
- Dividend yield
- —
- Payout
- —
- EPS
- -$2.41
- ROE
- -56.37%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- -0.34
- 52-week high
- $2.95
- 52-week low
- $1.77
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -99.6% over 5Y.
today you would have $3.25▼ -99.7%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 11 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $1.97 | $3.30 | $4.70 | $30.87 | $543.60 | $1,774.80 | $3,607.20 | $2,511.00 | $5,778.00 | $8,802.00 | $14,796.00 | |
| P/E | — | — | 3.8x | — | — | — | — | — | — | — | — |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| SNTISenti Biosciences Holdings, Inc. | $0.38 | — | 4.6x | — | -466.46% | $11.74M |
| PDSBPDS Biotechnology Corp | $0.21 | — | — | — | -543.97% | $11.8M |
| BLRXBioLineRx Ltd. | $2.60 | — | 0.7x | — | -46.72% | $11.36M |
| ADGMAdagio Medical Holdings, Inc. | $0.51 |
About the company
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has a strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
- 13
- Encinitas, United States
Company description provided by Yahoo Finance.